A study from the Medicine, Karolinska Institutet, Sweden shows that “Increased Arterial Blood Pressure and Vascular Remodeling in Mice Lacking Salt-Inducible Kinase 1.” This study was published in the 02 January 2015 issue of Circulation Research by Prof. Laura Brion, Dr. Alejandro M Bertorello and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Hypertension: LKB (Liver Kinase B1) decreases arterial blood pressure and vascular remodelling via up regulation of its target gene. Together, pharmacological formulations encompassing “LKB or its activators” may be used to decrease blood pressure.
Amount: $ 500
Undisclosed information: How LKB decreases arterial blood pressure and vascular remodelling
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Hypertension: LKB (Liver Kinase B1) decreases arterial blood pressure and vascular remodelling via up regulation of its target gene, 20/January/2014, 06.45 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
